Novo Nordisk aktie (NOVO B) | Pressmeddelande
Börskollen - Aktier, fonder och ekonominyheter
BörskollenFör dig med koll på börsen
•Nyhetsbrev: Hög rabatt och stora insynsköp – köp investmentbolaget

Pressmeddelanden från Novo Nordisk

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

GlobeNewswire • Idag 14:00

Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress

Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the ...

GlobeNewswire • 05 Sep 08:01

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity ...

GlobeNewswire • 31 Aug 09:09

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diab...

GlobeNewswire • 20 Aug 15:31

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 19 Aug 13:37

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

GlobeNewswire • 15 Aug 23:23

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 12 Aug 14:26

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 Aug 15:16

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 07 Aug 17:31

Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025

Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.

GlobeNewswire • 06 Aug 07:30

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

GlobeNewswire • 29 Jul 13:36

Novo Nordisk lowers sales and operating profit outlook for 2025

Novo Nordisk lowers sales and operating profit outlook for 2025

GlobeNewswire • 29 Jul 13:02

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemoph...

GlobeNewswire • 25 Jul 12:47

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people...

GlobeNewswire • 23 Jun 20:36

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new p...

GlobeNewswire • 22 Jun 21:35

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.

GlobeNewswire • 22 Jun 15:00

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – accor...

GlobeNewswire • 21 Jun 01:38

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

GlobeNewswire • 21 Jun 01:34

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

GlobeNewswire • 12 Jun 19:06

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and ...

GlobeNewswire • 10 Jun 14:00

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

GlobeNewswire • 16 May 13:19

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

GlobeNewswire • 16 May 13:02

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

GlobeNewswire • 14 May 12:59

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth...

GlobeNewswire • 12 May 08:01

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 09 May 13:22

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.

GlobeNewswire • 07 May 07:30

Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases

Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases

GlobeNewswire • 06 May 14:00

Novo Nordisk announces changes in Executive Management

Novo Nordisk announces changes in Executive Management

GlobeNewswire • 03 Apr 08:00

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

GlobeNewswire • 29 Mar 19:33

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and periphera...

GlobeNewswire • 29 Mar 15:33

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Resolutions from the Annual General Meeting of Novo Nordisk A/S

GlobeNewswire • 27 Mar 16:17

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

GlobeNewswire • 24 Mar 11:02

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 tri...

GlobeNewswire • 10 Mar 11:24

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

GlobeNewswire • 27 Feb 15:03

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 07 Feb 13:54

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

GlobeNewswire • 07 Feb 08:45

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 06 Feb 10:12

Novo Nordisk files annual report with the SEC

Novo Nordisk files annual report with the SEC

GlobeNewswire • 05 Feb 13:36

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.

GlobeNewswire • 05 Feb 07:30

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 04 Feb 13:57

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 27 Jan 14:05

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

GlobeNewswire • 24 Jan 11:19

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 20 Jan 15:32

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.

GlobeNewswire • 17 Jan 13:11

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 13 Jan 14:52

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

GlobeNewswire • 08 Jan 12:30

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 20 Dec 2024 13:47

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

GlobeNewswire • 20 Dec 2024 11:41

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, i...

GlobeNewswire • 18 Dec 2024 14:59

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 16 Dec 2024 13:52

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

GlobeNewswire • 16 Dec 2024 07:29

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites fro...

GlobeNewswire • 14 Dec 2024 06:08

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kid...

GlobeNewswire • 12 Dec 2024 14:47

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 09 Dec 2024 16:43

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufactu...

GlobeNewswire • 06 Dec 2024 19:11

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual mee...

GlobeNewswire • 03 Dec 2024 14:00

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 02 Dec 2024 12:46

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 25 Nov 2024 16:16

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 19 Nov 2024 14:33

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 18 Nov 2024 16:08

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 13 Nov 2024 17:18

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 12 Nov 2024 20:00

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 Nov 2024 22:22

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 08 Nov 2024 21:51

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

GlobeNewswire • 08 Nov 2024 21:47

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 Nov 2024 15:07

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 07 Nov 2024 18:27

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.

GlobeNewswire • 06 Nov 2024 07:41

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.

GlobeNewswire • 06 Nov 2024 07:30

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 05 Nov 2024 14:37

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

GlobeNewswire • 01 Nov 2024 13:13

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 28 Oct 2024 13:11

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 21 Oct 2024 14:50

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabete...

GlobeNewswire • 21 Oct 2024 11:26

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with h...

GlobeNewswire • 18 Oct 2024 11:32

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 14 Oct 2024 14:06

Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities

Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities

GlobeNewswire • 08 Oct 2024 10:00

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 07 Oct 2024 12:44

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 30 Sep 2024 13:02

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 23 Sep 2024 13:56

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

GlobeNewswire • 20 Sep 2024 14:43

Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function

Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and ...

GlobeNewswire • 19 Sep 2024 21:10

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 16 Sep 2024 15:15

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 09 Sep 2024 16:10

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 09 Sep 2024 15:55

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 30 Aug 2024 10:39

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 26 Aug 2024 15:44

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 20 Aug 2024 21:35

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 19 Aug 2024 14:48

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 14 Aug 2024 13:40

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 12 Aug 2024 14:31

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 12 Aug 2024 14:04

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 09 Aug 2024 20:29

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

GlobeNewswire • 08 Aug 2024 18:54

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.

GlobeNewswire • 07 Aug 2024 07:31

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 06 Aug 2024 13:15

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

GlobeNewswire • 29 Jul 2024 13:05

European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events

European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardio...

GlobeNewswire • 25 Jul 2024 17:08

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 22 Jul 2024 14:22

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme

GlobeNewswire • 15 Jul 2024 12:50